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Abstract
Background: Obsessive-compulsive disorder (OCD) is a heterogeneous neuropsychiatric condition, thought to have
a significant genetic component. When onset occurs in childhood, affected individuals generally exhibit different
characteristics from adult-onset OCD, including higher prevalence in males and increased heritability. Since
neuropsychiatric conditions are associated with copy number variations (CNVs), we considered their potential
role in the etiology of OCD.
Methods: We genotyped 307 unrelated pediatric probands with idiopathic OCD (including 174 that were part
of complete parent-child trios) and compared their genotypes with those of 3861 population controls, to
identify rare CNVs (<0.5 % frequency) of at least 15 kb in size that might contribute to OCD.
Results: We uncovered de novo CNVs in 4/174 probands (2.3 %). Our case cohort was enriched for CNVs in
genes that encode targets of the fragile X mental retardation protein (nominal p = 1.85 × 10−03; FDR=0.09),
similar to previous findings in autism and schizophrenia. These results also identified deletions or duplications of exons
in genes involved in neuronal migration (ASTN2), synapse formation (NLGN1 and PTPRD), and postsynaptic scaffolding
(DLGAP1 and DLGAP2), which may be relevant to the pathogenesis of OCD. Four cases had CNVs involving known
genomic disorder loci (1q21.1-21.2, 15q11.2-q13.1, 16p13.11, and 17p12). Further, we identified BTBD9 as a candidate
gene for OCD. We also sequenced exomes of ten “CNV positive” trios and identified in one an additional plausibly
relevant mutation: a 13 bp exonic deletion in DRD4.
Conclusions: Our findings suggest that rare CNVs may contribute to the etiology of OCD.
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Background
Obsessive-compulsive disorder (OCD) is a heteroge-
neous neuropsychiatric condition characterized by per-
sistent intrusive unwanted thoughts (obsessions) and
repetitive behaviours (compulsions) [1]. It is among the
most common neuropsychiatric disorders, with a life-
time prevalence of ~2 % [2]. Males and females are af-
fected in similar numbers (1:1 sex ratio), although males
typically experience symptoms earlier than do females
[1, 2]. First-degree relatives of individuals with OCD are
significantly more likely to have OCD than are relatives
of controls [1]. Classification of individuals into more
homogeneous subtypes has been used to increase the
likelihood of identifying causal factors [3]. One such ap-
proach takes advantage of the bimodal distribution of
age-of-onset, with one peak in childhood and another in
mid-adulthood [4]. The 30–50 % of individuals who first
experience symptoms before age 18 may represent a dis-
tinct subtype of OCD [5]. On average, these individuals
have worse symptom severity scores, respond less to
pharmacological interventions, and have higher rates of tic
disorders and attention deficit hyperactivity disorder
(ADHD) compared with individuals with adult onset OCD
[6–8]. Most important, the duration of OCD symptoms in
childhood is a significant predictor of how persistent these
behaviours will be in adulthood, stressing the significance
of early diagnosis and intervention [5, 6].
Higher heritability estimates in childhood-onset OCD
relative to adult-onset OCD emphasize a more substan-
tial role for genetic factors in these individuals, though
the identification of specific genetic susceptibility vari-
ants requires additional investigation [1]. Studies of gen-
etic linkage in large pedigrees and analyses of candidate
genes have identified potentially contributory loci, but
replication of these findings has been inconsistent [1].
The contribution of common variants to the disorder
was explored via two genome-wide association studies
(GWAS) [9, 10], and these studies only identified genes
of suggestive relevance, possibly due to insufficient
power. Altogether, findings from GWAS and candidate
gene studies suggest that OCD is complex in origin,
possibly involving perturbations in many genes, with
suggestive etiological evidence for DLGAP1, BTBD3,
SLC1A1, FAIM2, and PTPRD [1].
Gene dosage imbalances caused by rare copy number
variations (CNVs) have been identified as plausible con-
tributory factors in other neuropsychiatric conditions,
particularly those that are de novo in nature [11–13].
Higher levels of de novo copy number variation are
noted in individuals with a range of neuropsychiatric
conditions compared to the general population and are
typically a focal point of CNV studies of disease [14–16].
OCD traits often co-occur with such conditions, includ-
ing in 30–40 % of individuals with autism spectrum
disorder (ASD), [17] 7–17 % with schizophrenia, [18]
and 11–21 % with bipolar disorder [19]. One study so
far has examined the genome-wide contribution of rare
CNVs to OCD [20]. It identified an association trend be-
tween deletions at 16p13.11 and OCD. The relatively
large size cut-off used (500 kb) excluded the investiga-
tion of smaller CNVs.
To identify potentially contributory genetic factors in
OCD, we conducted a CNV screen using high-resolution
microarrays, which facilitated CNV calling down to
15 kb. We also performed exome sequencing of selected
families, in search of additional contributory factors.
Finally, we assessed the cohort with respect to its overall
burden of mutation and enrichment of variants in func-
tional gene sets.
Methods
Subjects and controls
Participants were recruited from four academic child
psychiatry sites: The Hospital for Sick Children, McMaster
University, University of Michigan, and Wayne State
University. Subjects were enrolled via clinics (site clinics,
other mental health providers and primary care physi-
cians), the internet (e.g., www.umhealthresearch.org at
University of Michigan), hospital and community bulletin
boards, and paid and public service advertisements in local
media.
All enrolled individuals (164 females and 143 males)
had symptoms first identified before age 18 (mean, 7.9 ±
3.5 years). Respective institutional ethics review boards
approved all procedures. Informed consent was provided
by capable adolescents. For younger children, parents or
other legal guardians provided written informed consent,
and the children gave verbal assent prior to participating
in the study. Criteria for diagnosis are in the Additional
file 1.
Our unrelated population control data were from
three cohorts: Cooperative Health Research in the
Region Augsburg (KORA) [21], the collaborative genetic
study of nicotine dependence (COGEND), [22] and the
Ontario Population Genomics Platform (OPGP) [23].
The same quality control procedures and CNV calling
algorithms applied to our subjects had been applied to
these controls.
Detection of rare copy number variants
We genotyped all 174 trios and 58 additional unrelated
probands using the CytoScan HD array, and 75 unrelated
probands using the OMNI 2.5 M array. We employed
multiple algorithms to call CNVs from the CytoScan HD
and OMNI 2.5 M microarray data. We defined a stringent
set of variants wherein each variant was called by at least
two algorithms (Additional file 2: Table S1) [24]. We
defined the ancestry and relatedness of the samples using
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PLINK [25] following methods previously described in
other studies (see Additional file 1) [26, 27]. This informa-
tion was used to exclude related probands or controls and
detect any sample mismatches.
To define rare CNVs, we first computed frequency
using a pooled set of stringent CNVs from cases and
controls, matching for ancestry, platform, and sex (Add-
itional file 1: Figure S1). We then removed those CNVs
present at >0.5 % frequency, using the 50 % reciprocal
overlap criteria [11, 28]. Next, we required that CNVs
overlap a region that is at least 75 % copy number stable
according to the CNV map of the human genome [28].
Finally, we used a cut-off of 15 kb and 10 probes for any
remaining CNVs, yielding a comprehensive and high-
quality list of rare CNVs from our case and control
cohorts. We first ascertained CNVs from all samples, in-
cluding individuals of non-European or mixed ancestry
and utilized the entire control set. We then restricted
our analysis to cases of European ancestry (for the sub-
sequent gene set analysis). Those CNVs listed in Table 1
are not present in population controls unless stated
otherwise in the table. We validated de novo events and
possible risk variants in proband and parental samples
(when available) using a secondary confirmation
method (a SYBR-green-based real-time quantitative
PCR (qPCR) or a TaqMan real-time PCR assay) [27,
29]. Primer sequences are available upon request from
SWS. Twenty-five of 28 CNVs of interest were vali-
dated (including all in Table 1 and 4/5 that were tagged
as being de novo). Suspected mosaicism in Case D was
confirmed using digital droplet qPCR (Additional file 1:
Figures S2 and S3). All coordinates refer to human gen-
ome assembly build GRCh37, hg19.
Burden of CNVs in cases and controls
We analysed the burden of all CNVs, and of deletions
and duplications independently. We also looked at CNV
burden in the following size ranges: >15 kb (all), 15–100,
100–500, >500 kb, and >1 Mb. A binomial logistic re-
gression analysis determined whether the differences in
gene rates (the average number of genes intersected by
CNVs per subject) between cases and controls were the
result of a biological mechanism or statistical chance.
We corrected for the number of CNVs and the total
length of CNVs in the subject in our model.
Gene set enrichment analysis
We tested gene set enrichment using the rare vari-
ants detected for individuals of European ancestry
(Additional file 1: Figure S4). This analysis focused
on events impacting protein-coding exons, and con-
sidered deletions and duplications separately. The
analysis consists of a case-control burden test with
correction for the different platforms and also for
global CNV burden modelled as total CNV gene
count by subject (i.e., penalization for large CNVs
that may drive results in an unspecific way). The
gene sets tested were comprised of genes associated
with neurological functions (Additional file 3: Table
S2) [11, 30]. Gene set burden enrichment was per-
formed using a logistic regression analysis deviance
test corrected for gene count and global burden
(Additional file 1). The genotyping platform used for
CNV calling was modelled as a covariate. We under-
took the analysis twice; first without exclusion cri-
teria, and second, by excluding neurodevelopmental
risk loci previously described [20, 31, 32]. This pro-
vided an opportunity to see whether any enrichment
signal was being driven by loci already recognized.
For final results, we utilized 15 % as the Benjamini-
Hochberg false discovery rate significance threshold.
Exome sequencing
For samples with notable CNV findings (Table 1), we se-
lected those 10 families for which adequate sample ma-
terial was available from the proband and both parents
for additional exome sequencing. This was conducted
using the Illumina HiSeq2500, following exome capture
with Agilent SureSelect Human All Exon V5 target en-
richment kit. We aligned sequences to the hg19 refer-
ence using Burrows-Wheeler Aligner (BWA) v0.5.9, and
used the Genome Analysis Toolkit (GATK) v1.1–28 to
detect single nucleotide and small insertion and deletion
variants. Rare variants were defined as those with a fre-
quency of <0.01 in 1000 genomes, National Heart, Lung,
and Blood Institute (NHLBI) Exome Variant Server and
Exome Aggregation Consortium (ExAc datasets; http://
exac.broadinstitute.org/). A Residual Variation Intoler-
ance Score (RVIS) [33] and Probability of Loss of Func-
tion (LoF) Intolerance score (pLI) [34] were retrieved for
each variant discovered. We confirmed the presence of
all variants in Table 2 in proband and parental samples
using Sanger sequencing [35].
Results
Rare copy number variations
To explore the contribution of rare CNVs to OCD, we
used a comprehensive CNV calling procedure with ex-
perimental validation of relevant variants. CNVs from
307 probands passed quality control, including 174 for
whom DNA from both parents was also genotyped. Of
these 307 probands, 259 were of European ancestry.
Data from 1773 European controls were treated as those
from the cases.
We uncovered 729 rare CNVs from these European
cases (Additional file 2: Table S1), and 5182 from the
European controls. This represented a mean of 2.81
and 2.92 rare CNVs per individual, respectively. We
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considered the number of genes intersected by CNVs
in cases compared with controls (Additional file 1:
Table S3), but found no statistically significant differ-
ence in this respect when looking at all CNVs, or at de-
letions and duplications independently. We also looked
for differences in a particular CNV size range but found
no greater global burden for rare CNVs in cases com-
pared with controls (Additional file 1: Table S3).
We screened 174 parent-child trios of all ancestries for
rare de novo CNVs. In four of these probands (2.3 %)
(Table 1, cases A–D), we uncovered a single de novo
CNV (sometimes in addition to inherited variants).
Various genomic syndromes have been observed in neu-
rodevelopmental disorders including autism, schizophre-
nia, and epilepsy [13]. We sought to identify in our cohort
rare CNVs that have been noted in some of these syn-
dromes using the DECIPHER database containing expert-
curated microdeletions and microduplications involved in
developmental disorders [36]. We also compared our re-
sults with a list of OCD and ASD risk genes [1, 11, 32, 37].
We identified four individuals (Table 1, cases E–H), each
with a CNV whose breakpoints were compatible with
those in DECIPHER. We identified other CNVs in genes
with possible relevance to OCD (Table 1, cases I–M), in
Table 1 Copy number variants of potential clinical significance in OCD subjects
Case Sample ID Sex Onset (year) CNV type Locationa Size (kb) Genes CNV source Exome seq
De novo
A 8961143 F 6 dup Xp22.31 305 VCX3B, KAL1 de novo ✓
B 896993 M 8 del 4p16.3 165 ADRA2C de novo
dup 3p26.3 1735 CNTN6, CNTN4 pat
C 1254 (188613) M 3 del 3p12.2 182 – de novo ✓
del 3q26.31 142 NLGN1 mat
del 7q36.2 115 DPP6 mat
dup 7q36.3 67 PTPRN2b pat
D 896713 F 10 dup (mosaic) 10q11.22- q11.21 239 ZFAND4, FAM21C,
MARCH8
de novo nsf c
dup 10q24.1 81 SLIT1b mat
Overlap with curated DECIPHER syndromesd
E HAM493 F 8 dup 15q11.2-q13.1 4918 13 genes n/a
F 0625-4262-1 M 8 dup 1q21.1-21.2 1799 15 genes mat ✓
G 1648 F 12 del 17p12 1404 8 genes mat ✓
dup 5p11-p12 e 1065 HCN1b pat
H 896573 M 9 dup 16p13.11 783 8 genes mat nsf
Genes implicated in other neurodevelopmental disorders
I 1298 M 5 dup Xp22.31 338 NLGN4X mat ✓
J 896673_a M 12 del 9q33.1 173 ASTN2, TRIM32 n/a
K 7542 M 12 del 9q33.1 163 ASTN2, TRIM32b n/a
L 0625-3695-3 M 12 dup 12q24.33 682 TMEM132D mat ✓
M 1688 F 3 del 18q22.1 2126 CDH19, CDH7 mat
FMRP target genes
N HAM193 M 12 dup 9p24.1 1489 PTPRD, C9orf123 n/a
O 896553 F 6 del 8p23.3 16 DLGAP2 pat ✓
P 1213 M 4 dup 18p11.31 62 DLGAP1 pat ✓
Overlap BTBD9
Q 0625-3790-3 F 8 del 6p21.2 107 BTBD9 pat
R 0625-7518-3 F 7 dup 6p21.2 469 GLO1, DNAH8, BTBD9 pat
Abbreviations: n/a parental sample not available, nsf no significant findings, FMRP fragile X mental retardation protein
aCoordinates can be found in Additional file 2: Table S1
bOne CNV of the same type with similar breakpoints was also identified in our population controls
cnsf indicates that exome sequencing of these probands identified no de novo or neurologically relevant loss-of-function mutations
dDECIPHER list of expert-curated microdeletion and microduplication syndromes involved in developmental disorders
eFound in the same patient, but not itself associated with DECIPHER syndromes
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gene targets of the enriched gene sets, particularly the fra-
gile X mental retardation protein (FMRP) (cases N–P),
and in a new plausible candidate, BTBD9 (cases Q–R).
Exome sequencing
In 10 of the trios where we discovered a potentially rele-
vant CNV (i.e., de novo, or involving gene(s) associated
with neurological function), we followed our CNV ana-
lysis with exome sequencing of the proband and parents.
We focused our analysis on any de novo mutations or
any predicted loss-of-function mutations in genes con-
sidered to play a role in neurological function. From
these families, we identified six de novo variants and
seven rare inherited loss-of-function mutations in genes
with a neurological role (Table 2). We subsequently ob-
tained RVIS and pLI scores for each of the genes to
show how able they are to tolerate functional genetic
variation and loss-of-function mutations, respectively.
Only one of the genes identified from exome sequen-
cing, AFF2, had an RVIS score in the tenth percentile
(among the most intolerant genes) and a pLI score of
above 0.9 (a score considered to be suggestive of patho-
genic LoF mutation) [34].
Gene set enrichment
Our initial analysis sought to identify gene set enrichment,
in cases compared with ethnically matched controls, from
CNVs that impact a gene’s coding sequence (Table 3;
Additional file 1: Table S4 and Additional file 4: Table S5).
We found such enrichment for CNVs in FMRP target
genes (nominal p = 1.85 × 10−03), both when we included
or excluded known neurodevelopmental risk loci from the
analysis. When such loci were included, cases were 1.75
times more likely to have one FMRP target impacted by a
CNV than were controls, and 4.38 times more likely to
have two FMRP targets impacted (Additional file 4: Table
S5). Much of the signal seemed to be driven by duplica-
tions (nominal p = 0.014), though the limited sample size
and false discovery rate (FDR) of 36 % cautions against
over-interpretation. When considering all loci and a more
relaxed FDR threshold (0.275) [38], cases were enriched
with CNVs for genes involved in nervous system develop-
ment (human neural function or pathway, nervous system
development (GO)) (nominal p = 0.019) and the broader
group encompassing genes involved in neurological func-
tion (human neural function or pathway, union, inclusive
(GO, KEGG, NCI, Reactome)) (nominal p = 0.020). Similar
results were generated when removing CNVs at known
neuropsychiatric disease loci.
Notable case findings
De novo copy number variants (Cases A–D)
Case A has a de novo duplication intersecting VCX3B
and KAL1 on chromosome X. KAL1 is involved in cell
adhesion, neurite outgrowth, and axon guidance. VCX3B
is expressed only in male germ cells. Her mother was di-
agnosed with an eating disorder.
We identified a de novo 165 kb deletion encompassing
ADRA2C in Case B. ADRA2C regulates neurotransmitter
release and modulates GABA release from the striatum.
B also carries a large 1.7 Mb duplication impacting
CNTN6 and part of CNTN4, inherited from his father
who has learning difficulties. CNVs involving each have
been noted in autism cases [11, 16].
Case C had onset of OCD at age 3 years, and also has
Tourette syndrome and ADHD. Parental phenotypes
Table 2 All de novo or neurologically relevant loss-of-function mutations from exome sequencing of selected families
Case Sample ID Position Gene Isoform Change Effect Source RVIS (%)a pLIb
A 8961143 chr4:69,403,498-69,403,498 UGT2B17 NM_001077 p.A480T Missense de novo 96.5 0.01
G 1648 chr18:3,102,478 MYOM1 NM_003803 p.G1190A Missense de novo 81.7 0.00
chrX:114,347,884-114,347,887 LRCH2 NM_020871 p.C730fs Frameshift del de novo 53.2 0.92
J 896553 chr14:24,677,345 TSSK4 NM_001184739 p.T337M Missense de novo 77.7 0.00
chr14:74,947,404 NPC2 NM_006432 c.548 + 1C > T Splice site mat 71.1 0.01
K 1213 chr9:2,824,808 KIAA0020 NM_014878 p.I348N Missense de novo 78.9 0.00
R 0625-3695-3 chr9:107,266,546 OR13F1 NM_001004485 p.M1I Missense de novo 95.9 0.00
USP54 NM_152586 p.R1395X Nonsense pat 91.4 0.00
C 1254 chrX:148,048,382-148,048,393 AFF2 NM_002025 p.992_996del Deletion mat 7.2 1.00
chr11:637,537-637,549 DRD4 NM_000797 p.A78fs Frameshift del mat N/A 0.00
chr3:129,155,547 MBD4 NM_003925 p.E314fs Frameshift ins mat 83.4 0.00
F 0625-4262-1 chr5:145,895,394 GPR151 NM_194251 p.R95X Nonsense mat 78.7 0.00
O 1298 chr19:11,325,007 DOCK6 NM_020812 p.Q1428X Nonsense mat 9.4 0.00
The above variants were validated in proband and parental samples using Sanger sequencing
aResidual Variation Intolerance Score
bProbability of Loss-of-Function Intolerance
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were not provided. Multiple CNVs included a de novo
deletion in a non-genic region, maternally-inherited de-
letions of NLGN1 and DPP6, and a PTPRN2 duplication
also seen in his father. Exome sequencing also revealed
three maternally-inherited variants: a 13 bp frameshift
deletion of DRD4 (a dopamine receptor gene), a 4-
amino-acid in-frame deletion of AFF2 (also known as
FMR2) and a single-base insertion in MBD4. NLGN1 en-
codes a protein involved in forming excitatory synapses
and maintaining synaptic plasticity [39]. Exonic CNVs of
NLGN1 and DPP6 have been identified in individuals
with autism [11, 40]. Duplications of PTPRN2 has been
implicated in ADHD [12]. Rare mutations in AFF2 have
been noted in ASD [41]. DRD4 has been previously as-
sociated with OCD [42].
Case D is mosaic for a large de novo duplication over-
lapping ZFAND4, FAM21C, and MARCH8. None of
these genes has been previously implicated in neuro-
psychiatric disorders. She also carries a rare exonic du-
plication in SLIT1, inherited from her mother who was
diagnosed with depression. SLIT1 is thought to play a
role in axonal navigation and neuron projection.
CNVs known to be associated with curated DECIPHER
syndromes
In female case E, we found a large 15q11-q13 duplica-
tion. About 1 in 500 children referred for genetic testing
for developmental delay or autism has a CNV at this
locus [43], and duplications of this region are among the
most common genomic rearrangements seen in ASD
probands, being present in 1–3 % of these individuals
[44]. This locus includes the GABAA receptor subunit
gene cluster, disturbances of which are proposed to in-
crease the risk of developing anxiety disorders [45]. The
duplication of this gene cluster may be an important
contributor to the observed OCD phenotype of this
individual.
From his unaffected mother, case F inherited a large
duplication overlapping the 1q21.1 locus, and he shares
the duplication with his male dizygotic twin who does
not have an OCD diagnosis. Duplications of this locus
are variably associated with both child- and adult-onset
neuropsychiatric conditions and congenital abnormal-
ities [46]. They have also been observed in some individ-
uals with ASD [47].
Case G has OCD with generalized anxiety disorder, so-
cial anxiety disorder, and specific phobia. We discovered
a large maternally-inherited deletion at 17p12—a locus
associated with hereditary liability to pressure palsies
(HNPP)—in this individual. Deletions of this locus usu-
ally manifest in patients as peripheral nerve problems
[48], though this patient has no such symptoms. This
deletion has been noted in asymptomatic individuals and
may not be relevant to the OCD phenotype of this indi-
vidual [48]. She also carries a paternally-inherited dupli-
cation impacting the first five exons of HCN1, a gene
encoding ion channels that facilitate synaptic integration
and plasticity. Phenotypic information was not available
for either parent.
We identified a maternally-inherited duplication over-
lapping the 16p13.11 recurrent microduplication locus
in case H. This locus is associated with neurocognitive
disorders, and is implicated in individuals with autism
[11] and some with OCD [20], though deletions (not du-
plications) were the significant finding in the latter.
CNVs in genes implicated in other neurodevelopmental
disorders
In addition to OCD, case I suffers from major depressive
disorder, social anxiety disorder, and a panic disorder.
We found a duplication of the first non-coding exon of
NLGN4X, inherited from his mother (who was not ex-
amined phenotypically). Functional studies of NLGN4X
have shown that the gene plays important roles with re-
spect to neuronal development and neurite formation
[49]. Elsewhere, brothers with Tourette syndrome—one
with autism as well, and the other with ADHD—had a
three-exon deletion of NLGN4X [50]. Interestingly, their
mother who also carried the deletion had anxiety and
depression, suggesting that variants of NLGN4X might
predispose to a range of neuropsychiatric phenotypes.
ASTN2, a gene that plays an important role in neur-
onal migration, was found deleted in two males. Case J
was previously reported by our group in an individual
Table 3 Summary of enriched gene sets
Gene set Size of
gene set
With known locia Without known loci
Nominal p value False discovery rate (FDR) Nominal p value FDR
FMR1 targetsb 840 0.00185 0.09 0.00312 0.16
Nervous system developmentc 1,874 0.0186 0.26 0.0633 0.46
Union inclusived 2,874 0.0205 0.26 0.0385 0.35
aLoci implicated in neurodevelopmental disorders
b“Human neural selected components, FMR1 targets” in Additional file 3: Table S2; deletions and duplications
c“Human neural function or pathway, nervous system development (GO)” in Additional file 3: Table S2; deletions and duplications
d“Human neural function or pathway, union, inclusive (GO, KEGG, NCI, Reactome)” in Additional file 3: Table S2; deletions and duplications
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with OCD and social anxiety [29]. Case K, the other in-
dividual with an ASTN2 deletion, has depression,
ADHD, and Tourette syndrome. Both variants overlap
the “critical region” at the 3’ end of the gene identified
in a previous study [29].
In case L, we identified a duplication of TMEM132D,
a gene implicated in panic disorder, and thought to con-
tribute to anxiety phenotypes [51].
Case M has OCD with trichotillomania, and a deletion
involving CDH7 and CDH19. Her parents were not
interviewed. Both genes encode members of the cad-
herin family—proteins that play an important role in
brain development.
CNVs involving FMRP target genes
In case N, we found a 1.5 Mb duplication involving
PTPRD, a gene that is highly expressed at the presynap-
tic terminal and regulates glutamatergic synapse devel-
opment, and is a target of FMRP. This variant
completely duplicates five of the six main isoforms,
suggesting that increased dosage of the gene product
may contribute to the disorder phenotype. In a large
GWAS for OCD, a single nucleotide polymorphism
(SNP) near this gene was also the marker with the
smallest p value [10].
Case O inherited from her unaffected father a single
exon deletion from DLGAP2—another FMRP target.
This is the first study to identify a CNV in DLGAP2 in
an individual with OCD. However, previously, two SNPs
in DLGAP2 were nominally associated with the orbito-
frontal cortex white matter volume in children with
OCD (although this association was not significant after
correction for multiple comparison) [52].
The duplication impacting DLGAP1 in case P involves
an exon that is considered to be “brain critical” [53].
This child also has Tourette syndrome, separation anx-
iety disorder, and oppositional defiant disorder. Though
he inherited this variant from his unaffected father, his
younger sister who carries the same variant was also di-
agnosed with OCD at age 4, and has social anxiety dis-
order, specific phobia, and transient tic disorder. Their
mother possesses some features of OCD-like behaviour,
but does not meet the criteria for diagnosis. This may
suggest that other maternally inherited genetic factors
also contribute to the phenotypes of the child.
CNVs impacting BTBD9
We identified two individuals with CNVs overlapping
BTBD9. Case Q has a 107 kb exonic deletion inherited
from her father (for whom phenotypic details were un-
available). Case R has OCD and Tourette syndrome, and
inherited a larger duplication that overlaps the 5’ end of
the gene. She inherited the duplication from her father
who has seasonal affective disorder. This being the first
time CNVs of BTBD9 have been identified in individuals
with OCD, we expanded our analysis by also inspecting
our unpublished microarray, exome, and whole-genome
sequencing data in autism cases for CNVs or loss-of-
function mutations in this gene. We found a previously
unpublished male ASD proband with a paternally-
inherited single-base-pair deletion, predicted to cause a
frameshift and premature truncation of the BTBD9 pro-
tein. This individual also displayed obsessive compulsive
tendencies. Though his father had no evidence of OCD
(only writing difficulties), the child’s paternal grandfather
had a host of psychiatric issues including depression,
poor social skills, substance abuse, OCD, and Tourette
syndrome. DNA was not available from the grandfather
to test for segregation of the variant.
Discussion
We found de novo CNVs in 2.3 % of OCD cases—a rate
lower than typically seen in other neurodevelopmental
disorders such as schizophrenia (4.5 %) [14], bipolar dis-
order (4.3 %), [14] cerebral palsy (7.0 %) [26], or autism
(4.7 %) [11], but slightly higher than for ADHD (1.7 %)
[12]. The de novo rate in population controls from
microarray is closer to 0.9–1.4 % [14, 54]. Although
there is some variation between the different microarray
platforms used, all are considered to be high-resolution
arrays and all focus on CNVs in comparable size
ranges to those we examined. As a result, a general
comparison can be attempted with the caveat that
this is a single study, and larger sample numbers for
all disorders would even better highlight any differ-
ences that might exist. In addition, disparities in the
selection of variants for validation and sample source
might play a minor role in the differences observed.
That said, there are also important biological reasons
that could explain the differences inde novo rates in
different disorders.
Individuals with autism, schizophrenia, and bipolar
disorder have reduced reproductive rates [55] making it
less likely that they pass on a newly acquired mutation;
although reduced fecundity is also noted in OCD, it is
only slightly lower than that of individuals without a
neuropsychiatric condition [56]. Therefore, inherited
genetic variation may play a more substantial role than
de novo events in the underlying genetic architecture for
OCD. We identified rare inherited CNVs at positions
congruent with curated DECIPHER syndromic loci, and
overlapping genes associated with other neurodevelop-
mental disorders, FMRP targets, or BTBD9. In 10/174
(5.7 %) of our trios, we identified an inherited genetic le-
sion that we propose might have contributed to the pa-
tient’s OCD phenotype. Four additional probands had
possibly pathogenic copy number changes of unknown
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inheritance. In all, we identified candidate variants of po-
tential significance to OCD in 18/307 cases (5.9 %).
Enrichment of CNVs in certain gene sets can highlight
specific pathways or functional categories that contribute
to OCD risk. In OCD cases compared with controls, we
identified significant enrichment of rare CNVs intersect-
ing genes involved in neurological function, particularly
targets of FMRP (Table 3). Three CNVs overlapping
FMRP targets—PTPRD, DLGAP1 and DLGAP2—were of
particular interest in this cohort. Two SNPs near
DLGAP1 showed the highest associations in a previous
GWAS of OCD [9]. A marker near PTPRD exhibited the
highest association with OCD in the second GWAS [10],
and the locus has also been implicated in OCD by link-
age studies [57, 58]. The enrichment in these targets is
of particular relevance, given FMRP’s high expression in
neurons and its role as a regulatory protein that alters
the translation of proteins involved in synaptic function
[59], making it essential for a range of cognitive pro-
cesses. This concurs with studies of ASD and schizo-
phrenia that suggest CNVs impacting FMRP targets
increase risk for neuropsychiatric conditions [11, 60].
However, in contrast to the larger role for FMRP dele-
tions in these disorders, duplications are potentially
more relevant for OCD (statistically significant in our
study, albeit with a high FDR). This may reflect an alter-
nate mechanism underlying some of the relationship be-
tween genotype and phenotype.
Studies of OCD and of other neuropsychiatric condi-
tions invoke a genetic model whereby the atypical devel-
opment or maintenance of synaptic connections
contributes to a neuropsychiatric phenotype [1, 61]. As a
result, many of the same candidate genes are emerging
across a range of neuropsychiatric disorders. Here, we
have once again uncovered ASTN2 variants in individ-
uals with a neuropsychiatric condition. A previous study
[29] that has shown CNVs of this gene often are ob-
served in ADHD, and one individual in our study has
this diagnosis in addition to OCD. We also identified a
potential new OCD risk gene, BTBD9, which encodes a
protein with a BTB/POZ domain. Proteins containing
this domain play a role in synaptic plasticity and neuro-
transmission and alter dendritic branching.
Conclusions
One particularly interesting area of further research
would be to apply complementary microarray, exome se-
quencing, or whole-genome sequencing approaches [41,
62]. In autism, findings from exome sequencing and
from CNVs are largely non-overlapping [63]. With this
precedent, here, we undertook exome sequencing in 10
trios in our study, one of which revealed a plausibly rele-
vant mutation (DRD4). This pilot study demonstrates
the importance of using multiple approaches to investi-
gate the genetic contribution to OCD.
We identified a number of CNVs that overlap risk loci
for other neurodevelopmental conditions. As in
McGrath et al. [20], we found no increased global CNV
burden in cases compared with controls. Although we
did not find 16p13.11 deletions in our study (the main
finding in McGrath et al. [20]), we did identify a duplica-
tion at this locus. Most of our variants of interest were
smaller than their 500 kb cut-off, stressing the import-
ance of examining variation at all size ranges in OCD.
There are important caveats that must be accounted
for when interpreting our study. The first is that our
statistical power is constrained by our small sample size.
Because of this, most of the rare variants that were iden-
tified in our cases only occurred once. As a result, we
were required to rely to a greater extent on previously
published work and functional studies to prioritize genes
of interest. In addition, the small sample size resulted in
higher false discovery rates than what we would wish,
necessitating follow-up studies in larger cohorts of OCD
patients. Unfortunately, in many of our families, we also
lacked extensive phenotypic details in some patients and
even more frequently, in parents, preventing more com-
prehensive genotype and phenotype correlation. That
said, our study presents new avenues for further investi-
gation and highlights some important candidate genes.
Most importantly, we reaffirm the extensive genetic het-
erogeneity in neuropsychiatric conditions, while demon-
strating overlap between genes uncovered here with
those of other neurodevelopmental conditions.
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